INCYTE CORP 8-K

What Happened On July 6, 2026, Incyte Corporation announced it has completed its previously announced acquisition of Vega Therapeutics, Inc., which is a wholly owned subsidiary of Star Therapeutics LLC. The company issued a press release announcing the completion; that release is attached as Exhibit 99.1 to the Form 8-K (Item 8.01).

Key Details

• Completion date: July 6, 2026.
• Target: Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.
• Announcement: Press release attached as Exhibit 99.1 to the 8-K.
• Filing: Reported under Item 8.01 (Other Events); Form 8-K signed by Richard Hoffman, EVP & General Counsel.

Why It Matters This filing confirms Incyte completed a merger/acquisition transaction, a strategic event that can affect the company’s pipeline, assets and future financial results. The 8-K does not disclose purchase price or detailed financial impact; investors should watch for subsequent SEC filings or company releases that provide purchase terms, integration plans, and any changes to guidance or pro forma results.